Lacosamide in the general population and in people with intellectual disability: Similar responses?

Epilepsy prevalence is approximately 0.6 - 1.0% across the worldwide general population [1]. It is much higher in the intellectual disability (ID) population, where around 22% have epilepsy [2]. It is also estimated that as many as one in four people with epilepsy (PWE) have an ID [3]. Whilst seizure control for all PWE is initially managed by licensed Anti-Epileptic Drugs (AEDs), those with ID are excluded from pre-market systemic trials [4]. Rates of treatment resistance are significantly higher in ID populations than general [5].

Source: Seizure: European Journal of Epilepsy - February 18, 2020 Category: Neurology Authors: Jon Allard, William Henley, Brendan Mclean, Adrian Sellers, Sharon Hudson, Sanjeev Rajakulendran, Adrian Pace, Sarah Pashley, Melissa Maguire, Monica Mohan, Shan Ellawela, Phil Tittensor, Sunil Ram, Manny Bagary, Rohit Shankar Source Type: research